220 related articles for article (PubMed ID: 37978195)
1. TOF
Hoenisch Gravel N; Nelde A; Bauer J; Mühlenbruch L; Schroeder SM; Neidert MC; Scheid J; Lemke S; Dubbelaar ML; Wacker M; Dengler A; Klein R; Mauz PS; Löwenheim H; Hauri-Hohl M; Martin R; Hennenlotter J; Stenzl A; Heitmann JS; Salih HR; Rammensee HG; Walz JS
Nat Commun; 2023 Nov; 14(1):7472. PubMed ID: 37978195
[TBL] [Abstract][Full Text] [Related]
2. Mass Spectrometry-Based Immunopeptidomics of Peptides Presented on Human Leukocyte Antigen Proteins.
ElAbd H; Franke A
Methods Mol Biol; 2024; 2758():425-443. PubMed ID: 38549028
[TBL] [Abstract][Full Text] [Related]
3. Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery.
Zhang B; Bassani-Sternberg M
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899131
[TBL] [Abstract][Full Text] [Related]
4. Sensitive, High-Throughput HLA-I and HLA-II Immunopeptidomics Using Parallel Accumulation-Serial Fragmentation Mass Spectrometry.
Phulphagar KM; Ctortecka C; Jacome ASV; Klaeger S; Verzani EK; Hernandez GM; Udeshi ND; Clauser KR; Abelin JG; Carr SA
Mol Cell Proteomics; 2023 Jun; 22(6):100563. PubMed ID: 37142057
[TBL] [Abstract][Full Text] [Related]
5. Identification of tumor antigens with immunopeptidomics.
Chong C; Coukos G; Bassani-Sternberg M
Nat Biotechnol; 2022 Feb; 40(2):175-188. PubMed ID: 34635837
[TBL] [Abstract][Full Text] [Related]
6. Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens.
Bassani-Sternberg M
Methods Mol Biol; 2018; 1719():209-221. PubMed ID: 29476514
[TBL] [Abstract][Full Text] [Related]
7. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
Freudenmann LK; Marcu A; Stevanović S
Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
[TBL] [Abstract][Full Text] [Related]
8. Unlocking the potential of microfluidics in mass spectrometry-based immunopeptidomics for tumor antigen discovery.
Stutzmann C; Peng J; Wu Z; Savoie C; Sirois I; Thibault P; Wheeler AR; Caron E
Cell Rep Methods; 2023 Jun; 3(6):100511. PubMed ID: 37426761
[TBL] [Abstract][Full Text] [Related]
9. Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows.
Partridge T; Nicastri A; Kliszczak AE; Yindom LM; Kessler BM; Ternette N; Borrow P
Front Immunol; 2018; 9():912. PubMed ID: 29780384
[TBL] [Abstract][Full Text] [Related]
10. Engineering Cell Lines for Specific Human Leukocyte Antigen Presentation.
Jin D; Loh KL; Shamekhi T; Ting YT; Lim Kam Sian TCC; Roest J; Ooi JD; Vivian JP; Faridi P
Methods Mol Biol; 2023; 2691():351-369. PubMed ID: 37355557
[TBL] [Abstract][Full Text] [Related]
11. The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune Diseases.
Vizcaíno JA; Kubiniok P; Kovalchik KA; Ma Q; Duquette JD; Mongrain I; Deutsch EW; Peters B; Sette A; Sirois I; Caron E
Mol Cell Proteomics; 2020 Jan; 19(1):31-49. PubMed ID: 31744855
[TBL] [Abstract][Full Text] [Related]
12. Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy.
Minegishi Y; Haga Y; Ueda K
Cancer Sci; 2024 Apr; 115(4):1048-1059. PubMed ID: 38382459
[TBL] [Abstract][Full Text] [Related]
13. The impact of immunopeptidomics: From basic research to clinical implementation.
Shapiro IE; Bassani-Sternberg M
Semin Immunol; 2023 Mar; 66():101727. PubMed ID: 36764021
[TBL] [Abstract][Full Text] [Related]
14. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Roerden M; Nelde A; Walz JS
Front Immunol; 2019; 10():3004. PubMed ID: 31921218
[TBL] [Abstract][Full Text] [Related]
15. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
[TBL] [Abstract][Full Text] [Related]
16. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.
Marcu A; Bichmann L; Kuchenbecker L; Kowalewski DJ; Freudenmann LK; Backert L; Mühlenbruch L; Szolek A; Lübke M; Wagner P; Engler T; Matovina S; Wang J; Hauri-Hohl M; Martin R; Kapolou K; Walz JS; Velz J; Moch H; Regli L; Silginer M; Weller M; Löffler MW; Erhard F; Schlosser A; Kohlbacher O; Stevanović S; Rammensee HG; Neidert MC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858848
[TBL] [Abstract][Full Text] [Related]
17. SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics.
Lim Kam Sian TCC; Goncalves G; Steele JR; Shamekhi T; Bramberger L; Jin D; Shahbazy M; Purcell AW; Ramarathinam S; Stoychev S; Faridi P
Front Immunol; 2023; 14():1107576. PubMed ID: 37334365
[TBL] [Abstract][Full Text] [Related]
18. Immunoprecipitation methods impact the peptide repertoire in immunopeptidomics.
Wacker M; Bauer J; Wessling L; Dubbelaar M; Nelde A; Rammensee HG; Walz JS
Front Immunol; 2023; 14():1219720. PubMed ID: 37545538
[TBL] [Abstract][Full Text] [Related]
19. IMBAS-MS Discovers Organ-Specific HLA Peptide Patterns in Plasma.
Wahle M; Thielert M; Zwiebel M; Skowronek P; Zeng WF; Mann M
Mol Cell Proteomics; 2024 Jan; 23(1):100689. PubMed ID: 38043703
[TBL] [Abstract][Full Text] [Related]
20. Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis.
Sirois I; Isabelle M; Duquette JD; Saab F; Caron E
J Vis Exp; 2021 Oct; (176):. PubMed ID: 34723952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
